Sign inJoin waitlistJoin the waitlist

Sylvia Kurz

Co-Director, Chênevert Family Brain Tumor Center · Yale Cancer Center

Credentials: · · · · · · · ·

History

Chênevert Family Brain Tumor Center · Yale Cancer Center
Present
Yale Cancer Center
Present
Yale School of Medicine
Present

Yale-New Haven Hospital
2017–2019
Massachusetts General Hospital
2016–2017
Massachusetts General Hospital
2016–2017
Dana-Farber Cancer Institute
2013–2016
Neurology
Case Western Reserve University/University Hospitals Cleveland Medical Center
2010–2011
Max-Planck-Institute for Neurobiology and Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University
Medizinische Fakultät, Ludwig-Maximilians-Universität München
2006–2010

Research

MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47
Brain · 2009 · 488 citations
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
eLife · 2020 · 138 citations
Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells
Brain Pathology · 2010 · 128 citations

Erik Sulman
8 papers
Dimitris Placantonakis
7 papers
Matija Snuderl
7 papers
Christine Cordova
6 papers
PW
Patrick Wen
6 papers
Andrew Chi
5 papers
David Zagzag
5 papers
John Golfinos
5 papers
Rajan Jain
4 papers
Daniel Orringer
3 papers
David Reardon
3 papers
Douglas Kondziolka
3 papers

Clinical trials

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
Principal investigator · Recruiting · Phase 2
RTOG Foundation, Inc.
2025–2030
AB154 Combined With AB122 for Recurrent Glioblastoma
Principal investigator · Active not recruiting · Early phase 1
Yale University
2021–2026
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
Principal investigator · Completed · Phase 2
NYU Langone Health
2018–2022
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
Principal investigator · Completed · Phase 2
NYU Langone Health
2017–2019